It is estimated that solid organ transplant recipients have a two-to fourfold greater overall risk of malignancy than the general population. Some of the most common malignancies after transplant include skin cancers and posttransplant lymphoproliferative disorder. In addition to known risk factors such as environmental exposures, genetics, and infection with oncogenic viruses, immunosuppression plays a large role in the development of cancer through the loss of the immunosurveillance process. The purpose of this article is to explain the role of immunosuppression in cancer and to review the classes of chemotherapeutics. The field of anticancer drugs is continually expanding and developing, with limited data on use in transplant recipients. This article aims to provide information on class review, adverse effects, dose adjustments, and drug interactions that are pertinent to the care of transplant recipients.
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Introduction
Advances in clinical skill and knowledge and the use of potent and effective immunosuppression have reduced 1-year acute rejection (AR) rates and improved 1-year patient survival across all organ types. Despite this progress, long-term survival rates have not dramatically improved. Although maintenance immunosuppression reduces AR rates, it is not without long-term complications, including infection, cardiovascular disease, nephrotoxicity, and malignancy. It has been estimated that solid organ transplant (SOT) recipients are at a two-to fourfold greater overall risk of malignancy than the general population (1, 2) . This risk is especially high for cancers associated with oncogenic viruses, such as posttransplant lymphoproliferative disorder (PTLD) from Epstein-Barr virus (EBV), Kaposi sarcoma (KS) from human herpesvirus 8 (HHV-8), and nonmelanoma skin cancer (NMSC) and anogenital cancers from human papillomavirus (HPV) (2) (3) (4) . The most common cancer after transplant is NMSC, specifically squamous cell skin carcinoma (SCSC), which has a risk >50-fold compared with that of the general population (5) (6) (7) (8) (9) . A study of cancer risk in SOT demonstrated an increased standardized incidence ratio for several cancer types, including lung (1.97), kidney (4.65), thyroid (2.95), and pancreas (1.46) (4).
Immunosurveillance and Immunosuppression
In conjunction with known risk factors for posttransplant malignancy such as genetic mutations, environment exposures, and the loss of control of oncogenic virus, it is well recognized that exposure to induction and maintenance immunosuppression is a risk factor for malignancy (10) .
In an immunocompetent state, the immune system works to prevent the growth and proliferation of cancer cells. This process has been described in three phases of immunoediting (elimination, equilibrium, and escape) (2, 11) . The first phase, referred to as elimination or cancer immunosurveillance, is activation of the innate and adaptive immune cells and molecules to protect normal cells from becoming tumor cells when exposed to prooncogenic stimuli (11) . Immune cells involved in this phase are CD4+ and CD8+ T cells (10) . The process may end here if immunosurveillance is able to successfully eliminate the cancer cells; however, some cancer cells get through to the equilibrium phase. At this phase, they are maintained in an immune-mediated latent period (2) . The final phase is the escape phase, in which tumor cells progress to clinical disease and/or metastasis (2, 10, 11) . In an immunosuppressed state, the mechanisms of immunosurveillance are altered, increasing the risk of malignancy.
Calcineurin inhibitors (CNIs; tacrolimus and cyclosporine) are the backbone of immunosuppression. Both CNIs exert their immunosuppressive action through binding and inactivation of calcineurin, resulting in inhibition of IL-2 production, thus inhibiting T cell activation and proliferation. By virtue of their mechanism of action, these medications impair natural immunosurveillance. Cyclosporine and tacrolimus have been found to upregulate VEGF and increase the expression of TGF-b 1 . Both TGF-b 1 and VEGF play roles in the development of cancer cell growth (2, 10, 12) . There has been evidence of elevated TGF-b 1 and VEGF in cancer patients; cancer cells themselves can secrete TGF-b 1 , which facilitates angiogenesis, cancer cell invasion, and metastasis (2, 12, 13) . The production of VEGF also promotes tumor angiogenesis. Maluccio and colleagues demonstrated a tacrolimus dose-dependent increase in TGF-b 1 in vitro and in vivo, suggesting that tacrolimus-induced TGF-b 1 may play a part in tumor progression (14) . A case-control study from Engels, et al demonstrated that in liver transplant recipients, those with lung cancer had higher circulating TGF-b 1 and VEGF than those without cancer (12) .
A study from Dantal et al evaluated two cyclosporinebased regimens, standard or low dose, in kidney transplant recipients (KTRs) at 1 year after transplant. There was a lower frequency of cancer in the low-dose group and no significant difference in graft function or survival, although the low-dose group had more episodes of AR, suggesting that the intensity of immunosuppression also has an impact on pro-oncogenicity (15) .
In addition, the use of CNIs can increase oncogenic viral replication of, for example, EBV, HHV-8, and HPV, and increase production of viral-inducing IL-1 and IL-6. Uncontrolled infection with these viruses can result in PTLD, KS, and skin and/or cervical cancers (2).
The antimetabolite immunosuppressive drugs commonly used after transplant include azathioprine (AZA) and mycophenolic acid (MPA). MPA is commercially available as mycophenolate mofetil, a prodrug of MPA, and mycophenolate sodium, a delayed-release formulation of MPA. AZA interferes with DNA replication and inhibits T lymphocyte proliferation. The use of AZA has been linked to SCSC, which occurs by limiting the natural DNA repair process necessary to mediate DNA mutations secondary to ultraviolet radiation exposure (10, 16) . A meta-analysis found a 56% higher risk of SCSC in organ transplant recipients (OTRs) who had been exposed to AZA compared with those who had not (16) .
The more contemporary antimetabolite mycophenolate inhibits the enzyme inosine monophosphate dehydrogenase, resulting in inhibition of T and B cell proliferation. There is less consistency of data regarding the risk of malignancy secondary to MPA (17) . A cohort study on long-term risk of malignancy in KTRs evaluated data from the Organ Procurement and Transplantation Network (OPTN) and United Network for Organ Sharing (UNOS) database and found there was not an increased risk of malignancy associated with mycophenolate use (18) . Crane et al reviewed data on PTLD cases over a 28-year period at their institution and similar cases from OPTN/ UNOS data. Patient cases with primary central nervous system (CNS) PTLD were more often associated with KTRs (vs. nonrenal transplants), EBV, and the use of mycophenolate compared with non-CNS PTLD cases. Furthermore, when the authors evaluated data from OPTN/UNOS, the use of mycophenolate and the lack of CNI use were associated with a risk of primary CNS PTLD, demonstrating a potential risk (19) .
A study from Coghill et al evaluated the association between immunosuppressive regimens in KTRs and heart transplant recipients and SCSC risk (8) . The primary objective was to evaluate whether MPA had the same skin cancer risk as AZA. Participants who received AZA were more than twice as likely to develop SCSC than those who did not (odds ratio [OR] 2.67), and those who received MPA had a lower risk of SCSC (OR 0.45) (8).
The newest maintenance immunosuppressant, belatacept, is a selective T cell costimulatory blockade agent.
During phase II and III trials in KTRs, there were safety concerns regarding belatacept because of an observed increased incidence of PTLD (20) (21) (22) . A total of 16 patients receiving belatacept developed PTLD, and seven of these cases had CNS involvement (23, 24) . Given these concerns, the U.S. Food and Drug Administration (FDA) approval carries a boxed warning for the risk of PTLD, especially in EBV-seronegative patients.
Last, data on the oncogenic potential of corticosteroids is not clear. It has been proposed that steroids may play a pro-oncogenic role by modulating the immunosurveillance mechanism; however, this has not been fully supported in trials (10) .
Induction therapy is divided into T cell-depleting and nondepleting agents. The nondepleting agents (basiliximab, daclizumab) have not consistently been associated with an increased risk of cancer after transplant (25, 26) . T cell-depleting therapies such as alemtuzumab, antithymocyte globulin (ATG), and muronomab-CD3 have been shown to confer a higher risk of posttransplant malignancy. A study by Caillard et al demonstrated a higher risk of PTLD in patients who received T cell-depleting therapy, especially for AR treatment (25) . Another evaluation found that ATG was associated with a higher risk of melanoma but not lymphomas or solid tumor cancers (27, 28) . This same study demonstrated an increased risk of non-Hodgkin lymphoma and colorectal and thyroid cancers in KTRs with the use of alemtuzumab, a finding that had not been seen in literature previously (27) .
Although not immunosuppressive, voriconazole, an antifungal used for prophylaxis and treatment in OTRs, has an increased risk of cutaneous SCSC in lung transplant recipients (29) . One retrospective study found a 73% increased risk of SCSC associated with voriconazole use after transplantation (29) .
Role of Mammalian Target of Rapamycin Inhibitors
The mammalian target of rapamycin (mTOR) inhibitors, possessing both immunosuppressant and anticancer activity, have a unique role. As an immunosuppressant, the inhibition of the mTOR pathway by everolimus and sirolimus results in inhibition of T lymphocyte activation and replication.
The role of the mTOR pathway in carcinogenesis has been well described (30, 31) . The PI3K/AKT/mTOR pathway plays an essential role in all living cells for growth, proliferation, survival, and motility (30, 31) . This pathway is upregulated by VEGF, epidermal growth factor, and insulin growth factor; the binding of these factors is activated in up to 50% of various malignancies. It is proposed that the anticancer effect of the mTOR inhibitor class is due to inhibition of several enzymes in the signaling pathway that favor cancer cell growth, such as VEGF, which is required for angiogenesis (30) (31) (32) ).
An area of interest is the use of mTOR inhibitors for chemoprevention. Data suggest lower rates of malignancy in patients who receive mTOR inhibitor immunosuppression. The CONVERT trial in KTRs demonstrated lower rates of malignancy at 12 and 24 mo in patients who converted to sirolimus (at 6-120 mo after transplant) compared with those maintained on CNI therapy (33); average time from transplant to sirolimus conversion was 38.8 and 36.3 mo, respectively, after transplant. There was no difference in the primary safety end point (composite of AR, graft loss, or death at 12 mo) between the two groups. The overall rate of malignancy per 100 person-years in the sirolimus group was 2.1 versus 6.0 in CNI continuation group (p < 0.001). NMSCs accounted for the majority of malignancies (34) . In post hoc analysis, neither recipient age or time from transplant accounted for the differences in malignancy rates. The findings of CONVERT were confirmed with a metaanalysis of studies in KTRs, with a reduction in NMSC associated with sirolimus (35) .
Several large registry trials have evaluated sirolimus and the incidence of posttransplant malignancies. Data from >4000 KTRs who received mTOR inhibitors after transplant found reduced incidence of NMSC in KTRs with de novo mTOR inhibition; no effect on other tumors was seen. NMSC reduction was limited to basal cell carcinoma (BCC), and there was no significant decrease in SCSC (36) . In addition, a large registry study of >32 000 KTRs given sirolimus at any time did not find lower incidence of cancer with sirolimus use; BCC and SCSC were not included in this study (37) .
An important factor regarding the use of mTOR inhibitors is the high rate of discontinuation due to patient intolerance. Discontinuation rates in CONVERT were 15.7% with sirolimus and 9.5% with CNI continuation (33) . Adverse effects include diarrhea, nausea, hypercholesterolemia, peripheral edema, mucositis, and delayed wound healing.
After transplant, mTOR inhibitors have been used in the treatment of hepatocellular carcinoma recurrence, skin cancers, and KS (2, 31, 32) . An important distinction between mTOR inhibitors for cancer treatment and maintenance immunosuppression is variation in doses. Everolimus, for example-FDA approved as Afinitor (Novartis, Basel, Switzerland) for the treatment of certain breast cancers, pancreatic neuroendocrine tumors, neuroendocrine tumors of gastrointestinal (GI) or lung origin, and renal cell carcinoma-is dosed at 5-10 mg daily (31) . Everolimus is available as Zortress (Novartis) at 0.75-1 mg twice daily for kidney and liver transplant maintenance immunosuppression (38) .
Modifications of Immunosuppression
Specific recommendations for modifications of immunosuppression following malignancy diagnosis in OTRs have not been well established. The most common approach is reduction or even elimination of maintenance immunosuppression. Given the increased risk of PTLD in OTRs, much data regarding reduced immunosuppression (RIS) following malignancy diagnosis come from this patient population (39) . Following the diagnosis of PTLD, for example, MPA may be discontinued, with 25-50% reduction or complete cessation of CNI therapy (39) . Modifications vary based on the extent of patient disease, with just a 25% reduction for limited disease or discontinuation of antimetabolites and CNI in those who are critically ill with extensive disease (40) . For some patients, RIS may be the only intervention necessary (41) .
RIS is often implemented along with standard treatments for skin cancer, such as surgery, radiation, and chemotherapy (6, 42, 43) . RIS is thought to potentially improve prognosis (reduce risk of metastasis) of current skin cancer or decrease the potential for subsequent skin cancers (43, 44) . In a survey study, renal, liver, and heart transplant physicians were given 13 different skin cancer scenarios and asked to rank immunosuppression reduction and subsequent risk to the allograft as none to severe; RIS was seen as an appropriate adjuvant therapy in the management of skin cancer in OTRs, especially in severe or life-threatening cases (44) .
The risk of potential rejection must be weighed against the benefits of RIS or withdrawal. One study evaluated modification to maintenance immunosuppression in 87 KTRs with hematological or solid tumor cancers. There were significant reductions in AZA, cyclosporine, and tacrolimus exposure with a reported low risk of allograft rejection (6%) following RIS that was reversible with pulse steroids (45) .
The clinical implications following RIS will differ based on organ type. The risk of rejection and subsequent patient morbidity or mortality from underimmunosuppression in a KTR may be perceived differently compared with heart or lung recipients, depending on each situation. In the survey discussed previously, as reduction in baseline immunosuppression became more severe, a more severe risk of rejection in heart allografts was predicted (44) .
A prospective study of 16 patients (13 heart transplant recipients and three KTRs) with PTLD evaluated a sequential treatment algorithm-two different immunosuppression reduction strategies, interferon (IFN), and chemotherapy (46) . The two strategies implemented for immunosuppression reduction were AZA discontinuation and either 75% CNI reduction for up to 10 days or 50% CNI reduction for up to 2 weeks; CNI could be further reduced to 25% of original dose for an additional week. The RIS strategy was based on clinical urgency. Following RIS, six patients (38%) had documented AR; all were reversible with treatment.
In a retrospective analysis of KTRs with NMSC or noncutaneous malignancy (NCM) after transplant, a diagnosis of NCM was a strong risk factor for graft failure; NMSC was not associated with graft failure. When the authors evaluated the impact of immunosuppression reduction, graft failure after NCM was not affected by RIS, suggesting that causes other than chronic rejection were responsible (47) .
Risk of allograft rejection associated with specific cancer therapies, such as interferon therapy and checkpoint inhibitors, is discussed in the respective sections later in this review.
Another option is conversion to an mTOR inhibitor. In a study of 15 KTRs with biopsy-proven KS, immunosuppression was converted from cyclosporine to sirolimus. All 15 participants had complete clinical and histological clearance of KS lesions on biopsy at 6 mo (32). Hoogendijk-van den Akker et al evaluated 155 KTRs with at least 1 biopsy-confirmed cutaneous invasive SCSC who were either continued on maintenance immunosuppression or converted to sirolimus. The primary end point was new cutaneous invasive SCSC within 2 years of conversion. There was a nonsignificant 24% reduction in new cutaneous invasive SCSC within the study period (48) . Of note, there was a 42% discontinuation rate in the sirolimus arm due to intolerable adverse effects.
In heart transplantation, malignancy is a common indication for mTOR conversion (49). Euvrard et al published a study of 10 heart transplant recipients with skin tumors or fast-growing SCSC who were converted to everolimus from cyclosporine or who had everolimus initiated in addition to cyclosporine minimization. The number of skin tumors per patient after starting everolimus was lower than in the months prior to everolimus initiation (50) .
Vascularized Composite Allografts
Vascularized composite allotransplantation has been a growing arena of surgical skill and transplantation since the 1990s. Successful vascularized composite allografts (VCAs) in humans have included hands, forearms, face, abdominal wall, lower extremities, and several other tissues and body parts (51) . VCAs are highly immunogenic and require immunosuppression, putting recipients at similar risks of infections and malignancy as OTRs. Although experience is limited, there have been case reports regarding postgraft NMSC (BCC and SCSC).
Chemotherapeutics
The aim of the remainder of this article is to describe contemporary cancer therapies. Data regarding the use of chemotherapy in SOT is limited. This broad overview of medication classes will include FDA-approved indications, adverse effects, monitoring, and important clinical information. Table 1 provides a summary with drug classes and names, toxicities, and events that warrant dose modifications.
Taxanes
The taxanes are one of the most powerful classes available. First isolated in 1971 from the bark of the Pacific Yew (Taxus brevifolia) tree, they have been widely used in the treatment of solid tumor malignancies (52) . Drugs in this class include paclitaxel, docetaxel, and cabazitaxel.
The taxanes exert their antineoplastic activity through stabilization of the cell microtubules. Microtubules, which are composed of tubulin dimer subunits, are required for several cell functions, including cell division ( Figure 1 ). Taxanes bind to tubulin, stabilizing microtubules and thus inhibiting cellular mitosis, and cause cell cycle arrest (52, 53) .
Common toxicities include myelosuppression, nausea and vomiting, and hypersensitivity reactions (38) . Alopecia is a common toxicity limited to paclitaxel and docetaxel (54) . Paclitaxel is uniquely associated with peripheral neuropathies and myalgias, whereas docetaxel causes fluid retention.
The taxanes are substrates for the CYP3A4 enzyme and Pglycoprotein. Table 2 lists common inhibitors and inducers of the CYP system. Given this extensive liver metabolism, dose reductions are necessary with hepatic dysfunction.
Paclitaxel and docetaxel are used to treat non-small cell lung cancer (NSCLC) and breast, ovarian, head and neck, and gastric cancers (52, 55) . Paclitaxel is also used in KS and cervical and esophageal cancers (52) . Cabazitaxel is used exclusively for prostate cancers. In a small case series of KTRs with KS, paclitaxel use was successful in achieving complete remission (56) . Other limited experiences in transplant suggest that paclitaxel can be used safely after SOT (57).
Vinca Alkaloids
Another class of antimicrotubule agents is composed of the vinca alkaloids-vincristine, vinblastine, and vinorelbine ( Table 1 ). The vinca alkaloids destabilize microtubules, particularly acting at the mitotic spindle, resulting in delayed cell cycle progression and eventual apoptosis (52,58).
Vincristine's primary toxicities are constipation (paralytic ileus) and neurotoxicity, ranging from peripheral neuropathy to gait abnormality and loss of deep tendon reflexes (54). Vinblastine's and vinorelbine's dose-limiting toxicity is neutropenia. Class toxicities include alopecia, syndrome of inappropriate antidiuretic hormone, cardiac ischemia, chest pain, and Raynaud's phenomenon (54) . These agents are vesicants and lethal if administered intrathecally.
Vinca alkaloids undergo extensive hepatic metabolism via CYP3A4. Caution should be used in patients with liver dysfunction and when used with CYP3A4 inhibitors and/ or inducers.
Vincristine and vinblastine are primarily used in lymphoma, KS, and testicular cancer. Vinorelbine is primarily indicated in NSCLC and breast, cervical, and ovarian cancers (52) .
Alkylating Agents
Alkylating agents were introduced >50 years ago and continue to be used extensively (59) .
Alkylating agents are cell cycle nonspecific; therefore, they target all phases of the cell cycle and exert their antitumor effects on rapidly dividing tissues ( Figure 1 ) (59) . Generally, cytotoxic effects of these agents are a result of alkylation of DNA, causing fragmentation of DNA and mispairing of DNA bases, disrupting DNA synthesis and cell division (52) . Table 3 describes therapeutic uses, toxicities, and pertinent drug interaction information. The common toxicity of alkylating agents is myelosuppression. When used for PTLD treatment in OTRs (cyclophosphamide, doxorubicin, vincristine, and prednisone), grade 3 and/or 4 neutropenia was a significant side effect experienced by nearly all patients (60).
Platinum Analogs
The platinum analogs (cisplatin, carboplatin, and oxaliplatin), a subset of alkylating agents, are used to treat solid tumors. Cisplatin is used in bladder, ovarian, and testicular malignancies. Carboplatin is the most diversely used platinum agent and has clinical efficacy in a variety of solid tumor and hematological cancers (52) . Oxaliplatin is approved for the treatment of colon and colorectal cancer ( Table 1 ).
The platinum agents target DNA and exert their activity by reacting at the N7 position of guanine and adenine to form adducts, which form intra-or interstrand crosslinks and are responsible for the platinum analogs' cytotoxicity via impairment of DNA replication and transcription, resulting in apoptosis (52) .
The platinum analogs comprise of a complex between carrier ligands and leaving group structures, which are responsible for the antitumor activity. The differences in leaving groups among the platinum analogs affect plasma protein binding, half-lives, and clearance rates. Oxaliplatin, for example, is less easily displaced; therefore, it has less plasma protein binding, a longer half-life, and a higher rate of renal clearance.
Overlapping toxicities among the platinum analogs are nausea and vomiting, with cisplatin carrying the highest emetic potential. Myelosuppression is common with carboplatin, whereas oxaliplatin's dose-limiting toxicity is neurotoxicity (e.g. peripheral neuropathy). The major toxicities of cisplatin include myelosuppression, nephrotoxicity, neurotoxicity, and ototoxicity (38, 54, 61) . Cisplatin-associated nephrotoxicity is minimized with administration of intravenous fluids. Given the high propensity of nephrotoxicity, cisplatin is contraindicated in preexisting renal impairment, and use in KTRs is limited. One case report suggests that a cisplatin-based chemotherapy regimen was well tolerated without detriment to allograft function (62) .
Anthracyclines
The anthracyclines are considered to be one of the most effective and widely used anticancer therapies for solid tumor and hematological malignancies (63) . This class includes doxorubicin, daunorubicin, epirubicin, and idarubicin. Although the exact mechanism of action remains unclear, they are thought to exert their activity through several mechanisms: (i) direct binding or intercalating DNA; (ii) generation of free radicals, leading to DNA damage; and (iii) inhibition of DNA repair via inhibition of topoisomerase II. The overall impact is inhibition of DNA and RNA synthesis, leading to cell apoptosis (52, 63) . Adverse effects include myelosuppression, mucositis, hand-foot syndrome (doxorubicin), alopecia, nausea and vomiting, and cardiotoxicity (54) .
In a study of 18 OTRs, anthracycline-based chemotherapy was used to treat PTLD along with RIS. Of the 18 patients, 14 achieved complete remission. Risk of myelosuppression and toxicity from chemotherapy was decreased by concurrently reducing maintenance immunosuppression (64) .
Cardiotoxicity from anthracyclines was identified early in clinical use and is considered to be a risk of cumulative exposure. It can present as acute toxicity (tachyarrhythmia and hypotension) or chronic cardiotoxicity (heart failure) (65) . This toxicity occurs from generation of reactive oxygen species, resulting in direct damage to the myocardium. Chronic toxicity is largely irreversible and peaks at 1-3 mo of therapy. Preventive measures include routine cardiac monitoring. In patients with history of cardiac disease, risk versus benefit must be considered before initiating therapy. Dexrazoxane is a metal-chelating agent that reduces free radical-induced myocardial toxicity and can provide a cardioprotective benefit in selected patients.
Topoisomerase I Inhibitors (Camptothecins)
Topotecan and irinotecan, used in the treatment of solid tumors, act by inhibiting topoisomerase I, causing double-stranded DNA damage and resulting in interruption of DNA replication (66) .
Irinotecan is used in metastatic colorectal cancer. Adverse effects are largely GI-related; diarrhea associated with this therapy can be severe, requiring hospitalization for hydration and symptom management (38) . Irinotecan is hepatically metabolized to an active metabolite, SN-38 (67) . Patients with a polymorphism for the enzyme responsible for conjugating SN-38 may experience increased toxicity and require dose reduction.
Topotecan is used to treat cervical, ovarian, and small cell lung cancers. Side effects are primarily myelosuppression. It is metabolized both in the plasma and in the liver and cleared renally. Dose adjustments are necessary for liver and/or renal dysfunction (Table 1) .
Antimetabolites
The antimetabolites are divided into three subclasses: folate, pyrimidine, and purine analogs. This class of medications inhibits DNA synthesis, DNA repair, and cell replication.
The folate analogs include methotrexate, pemetrexed, and pralatrexate. These drugs act by inhibition of dihydrofolate reductase, an essential enzyme in folate metabolism (52) . Methotrexate is widely used across solid tumor and hematological cancers and for autoimmune disorders. Pemetrexed's niche use is in lung malignancies, and pralatrexate is primarily used for peripheral T cell lymphoma (68) .
The folate analogs are associated with myelosuppression, mucositis, and diarrhea. Pemetrexed and pralatrexate are associated with dermatological toxicities, including handfoot syndrome, skin rashes, and pruritus (54) . Administration of vitamin B12 and folic acid can ameliorate adverse effects.
Methotrexate is hepatically metabolized and renally cleared; therefore, methotrexate therapeutic drug monitoring is recommended. Drug monitoring is not routinely used for pemetrexed or pralatrexate, but patients with renal dysfunction may require dose adjustment.
The purine analog subclass, commonly used for leukemia, includes 6-mercaptopurine (6-MP), 6-thioguanine (6-TG), fludarabine, cladribine, nelarabine, and clofarabine. These drugs exert their activity by their conversion into enzyme analogs in the purine metabolic pathway, inhibiting the critical enzymes needed for DNA synthesis and leading to DNA damage and apoptosis.
Both 6-MP and 6-TG are administered orally; however, absorption and bioavailability is erratic. 6-MP requires xanthine oxidase for conversion to its inactive metabolite; drugs that inhibit this enzyme (e.g. allopurinol)
should not be used concomitantly. Patients with thiopurine methyltransferase (TPMT) gene mutations are at risk for increased toxicity and may require dose reductions. Toxicities associated with 6-MP and 6-TG include myelosuppression, diarrhea, nausea and vomiting, stomatitis, and loss of appetite (54) . These drugs are metabolized hepatically and in the GI mucosa and excreted renally.
Fludarabine, cladribine, nelarabine, and clofarabine are further classified as purine deoxynucleoside analogs. These drugs incorporate themselves directly into DNA to terminate DNA replication. Adverse effects include myelosuppression and immunosuppression. The additional immunosuppressive activity confers a higher risk of opportunistic infections. Clofarabine is associated with cardiovascular toxicities including tachycardia and capillary leak syndrome. Neurotoxicity with fludarabine, cladribine, and nelarabine can occur and is manifested as seizure-like activity, weakness, confusion, and possibly coma (54).
The pyrimidine analogs alter the pyrimidine metabolic pathway, resulting in inhibition of DNA synthesis. This class includes 5-fluorouracil (5-FU), capecitabine, cytarabine, and gemcitabine. Capecitabine (prodrug of 5-FU) and 5-FU are commonly used in colon, breast, hepatocellular, and pancreatic cancers (52) . Gemcitabine is used in solid tumors including NSCLC and pancreatic, breast, and bladder cancers as well as Hodgkin lymphoma. Cytarabine is primarily utilized in leukemias and lymphomas.
Capecitabine has been studied in the treatment and prevention of recurrent skin cancers in OTRs. In a case series of three patients treated with capecitabine for skin cancer, all had improvements in skin lesions (69) . When used in SOT patients with prior NMSC for recurrence prevention, there was a decreased incidence rate of skin lesions during capecitabine treatment (70) .
Primary toxicities of 5-FU and capecitabine are GI-related, including diarrhea, nausea and vomiting, and mucositis. Both agents cause coronary artery vasospasms, resulting in chest pain symptoms. Myelosuppression is common with 5-FU, whereas hand-foot syndrome is seen with capecitabine.
Gemcitabine causes GI toxicities, myelosuppression, and flulike symptoms. Patients may experience pulmonary toxicities, including dyspnea, pulmonary edema, and pulmonary fibrosis. Cytarabine toxicities include myelosuppression, diarrhea, nausea and vomiting, handfoot syndrome, ataxia, and "cytarabine syndrome," which is characterized by fever, malaise, arthralgia, and myalgia (52) .
Monoclonal Antibodies
One of the great advances in cancer therapeutics in the last two decades is the development of monoclonal antibodies. These drugs are targeted to act on specific antigens on cell surfaces to elicit an antitumor response. This section will discuss frequently used monoclonal antibodies but is not all-encompassing.
One of the first monoclonal antibodies available was rituximab. This drug acts directly by binding to CD20 antigen on the surface of B cells, activating complementdependent B cell cytotoxicity. Rituximab's place in therapy is largely for the treatment of non-Hodgkin PTLD and other lymphomas. Side effects include infusion-related reactions, hypotension, edema, and fatigue (Table 1) .
Brentuximab vedotin is a conjugate monoclonal antibody directed against CD30. It is used in Hodgkin lymphoma and anaplastic large cell lymphoma (52) . Toxicities include peripheral neuropathy, skin rash, nausea, and myelosuppression.
Bevacizumab is a monoclonal antibody that binds to and neutralizes VEGF, which is necessary for tumor angiogenesis. Bevacizumab is used in NSCLC; cervical, ovarian, and renal cell cancers; and glioblastoma (52) . Toxicities include hypertension, GI perforation, osteonecrosis of the jaw, and hemorrhage.
Trastuzumab was one of the first monoclonal antibodies to be used in breast cancer and is a mainstay in human epidermal growth factor receptor 2 protein (HER-2)-positive breast cancer (71) . This antibody targets HER-2 and elicits complement-dependent cytotoxicity. Side effects include cardiotoxicity and pulmonary and renal toxicities. More recently, a conjugate of this drug, adotrastuzumab emtansine, has offered an additional mechanism of antitumor effect through antimicrotubule activity. Additional adverse effects are peripheral neuropathy and hepatotoxicity. Pertuzumab is another anti-HER-2 antibody used in combination with trastuzumab for more complete HER-2 blockade (52).
Cetuximab and panitumumab directly bind to epidermal growth factor receptor and other ligands to inhibit cellular growth. These antibodies are used in the treatment of colorectal and head and neck cancers. Both agents cause dermatological toxicities. A serious adverse effect of cetuximab is sudden cardiac or pulmonary arrest.
Hormone Therapies
Hormonal agents are a mainstay in the treatment of hormone-sensitive solid tumors, such as breast, prostate, and uterine carcinomas. This section will focus on selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), estrogen receptor (ER) downregulators, antiandrogens, and androgen receptor antagonists (Table 1) .
Tamoxifen is an important SERM in the prevention and treatment of ER-positive breast cancer; it blocks translocation and nuclear binding of the ER, inhibiting transcription and estrogen stimulation (72) . Common side effects include hot flashes and increased risk of venous thromboembolic events (54) . Tamoxifen has protective effects on bone density in postmenopausal women but a negative effect on bone density in premenopausal women. In addition, tamoxifen's estrogenic properties increase the incidence of endometrial cancer after menopause. Concomitant use with CYP2D6 inhibitors alters the activation of tamoxifen its active metabolite, endoxifen, by lowering concentration and efficacy (54) . CYP3A4 inhibitors or inducers may also affect concentrations of tamoxifen and its active metabolites.
The AIs block the final step in the conversion of androgen to estrogen, thus halting estrogen synthesis to treat ER-positive breast cancer in postmenopausal women (52) . This includes anastrozole, letrozole, and exemestane. Side effects include decreased bone marrow density, arthralgia, myalgia, fatigue, and hot flashes (38) . Exemestane is metabolized by CYP3A4 and prone to drug interactions.
The antiandrogens-flutamide, bicalutamide, nilutamide, abiraterone, and enzalutamide-are used in the treatment of prostate cancer. Flutamide, bicalutamide, and nilutamide inhibit uptake and binding of androgen to tissues and have similar toxicity profiles, including decreased libido, hot flashes, nausea, vomiting, and diarrhea (52) .
The novel antiandrogens used in the treatment of prostate cancer are abiraterone and enzalutamide. Abiraterone blocks the formation of testosterone precursors by irreversibly inhibiting CYP17, a principle enzyme in androgen synthesis. A major toxicity with abiraterone includes mineralocorticoid excess symptoms, including hypokalemia, hypertension, and edema due to increased levels of adrenocorticotrophic hormone; coadministration of steroids improves these symptoms (54). Abiraterone is a major CYP3A4 substrate. Enzalutamide uniquely binds to the androgen receptor to impair nuclear translocation, DNA binding, and mobilization of cofactors, thus leading to cell death (52) . Toxicities include peripheral edema, hypertension, fatigue, hot flashes, and neutropenia. Posterior reversible encephalopathy syndrome and seizures have also been observed (54). Enzalutamide is a major CYP2C8 and CYP3A4 substrate.
Targeted Therapy
The newest frontier of anticancer therapy is the development of targeted therapies. These drugs have been designed to target specific kinases involved in the proliferation and growth of cancer cells. The breadth and depth of this evolving class of therapeutics is beyond the scope of this article; however, some of the most pertinent to SOT recipients will be discussed.
Targeted therapies used in the treatment of certain skin cancers include the BRAF inhibitors vemurafenib and dabrafenib and the MEK inhibitor trametinib. These targeted therapies are used for patients with BRAF V600 mutated metastatic or unresectable melanoma (52) . The adverse effects of vemurafenib and dabrafenib include dermatological toxicities, such as rash and photosensitivity. Other side effects include fatigue, arthralgia, myalgia, nausea and vomiting, diarrhea, and ocular and hepatic toxicity (54) . Both drugs are CYP3A4 and P-glycoprotein substrates and thus are prone to drug interactions.
Toxicities of trametinib, a MEK inhibitor, include bone marrow suppression, left ventricular dysfunction, dermatologic toxicities, venous thromboembolism, interstitial pneumonitis, and hepatotoxicity (54) . Table 4 lists information on additional targeted therapies available.
Checkpoint Inhibitors
Cancer immunotherapy is an emerging area of drug development changing the landscape of cancer therapy.
By stimulating the immune response of T cells against cancer antigens, immunotherapy produces an antitumor effect that inhibits regulatory pathways that are important for tumor progression. Other mechanisms of immunotherapy include stimulation of effector cells, active immunization, and adoptive immunotherapy (52) . Checkpoint modulators are a subcategory of immunotherapy of growing interest. Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an immunosuppressive costimulatory receptor found on activated T cells. Binding of CTLA-4 to antigen-presenting cells results in T cell inhibition; as such, blockade of CTLA-4 allows activation and proliferation of T cells to produce antitumor responses (73) . Ipilimumab is the first CTLA-4-blocking monoclonal antibody utilized in the treatment of melanoma.
Another target of immunotherapy is programmed cell death 1 (PD-1), a checkpoint modulator that is expressed on activated T cells. Through its interaction with PD-L1, its corresponding ligand, T cell functionality is suppressed (74) . The PD-1 pathway is distinct from the CTLA-4 pathway by acting at a later time point during T cell and tumor cell interaction (75) . Nivolumab is an anti-PD-1 monoclonal antibody for the treatment of head and neck cancer, renal cell carcinoma, melanoma, and Hodgkin lymphoma. Pembrolizumab is a newer anti-PD-1 monoclonal antibody used in the treatment of melanoma, NSCLC, and head and neck cancer (54) .
Severe immune-mediated toxicities can occur with both CTLA-4 and PD-1 inhibitors, such as colitis, dermatitis, hepatotoxicity, and hypophysitis (Table 4) . Acute interstitial nephritis reported with checkpoint inhibitors is also thought to be an immune-related adverse event. Although the mechanism needs further investigation, it is thought to be the result of enhancing autoreactive T cells, resulting in organ-specific damage (76, 77) . This is of particular concern for KTRs.
Another concern of using checkpoint inhibitors in transplant is that the heightened T cell responses will elicit an AR. Several case reports on AR subsequent to the use of anti-PD-1 therapies have been published, as well as AR in patients after both anti-CTLA-4 and anti-PD-1 therapies (74, (78) (79) (80) . There are also reports of successful use of ipilimumab in OTRs without AR occurring (81, 82) .
Other Therapies Biologics, such as IFNs, have also been used in the treatment of malignancies, including PTLD and advanced melanoma. IFNs are immunomodulatory and elicit activation of T cells, macrophages, and monocytes and can stimulate production of cytokines. These immune-stimulatory effects can be deleterious to OTRs, increasing the risk of AR. In the study by Swinnen, et al of sequential immunosuppression reduction, IFN, and chemotherapy in PTLD, 13 of 16 patients received IFN-a2B. There were two rejections, one of which was fatal, resulting in graft loss and patient death (46) . The largest body of evidence on IFN in OTRs comes from the hepatitis C literature (83). Walter et al studied 70 liver transplant recipients receiving IFN for hepatitis C; 15 patients experienced AR during therapy. The AR episodes were treated by temporarily stopping IFN, increasing immunosuppression, and/or steroid pulse (84) .
Pharmacogenomics
Cancer pharmacogenomics are increasingly becoming more important in determining relationships between drug response and human genetics to individualize cancer therapy. Targeted therapies are expanding from significant discoveries of tumor mutations, molecular markers, and other genomic properties (85) . Because responses to therapy vary among individuals, the identification of drug-targeted genes, enzymes, and patientspecific genetic variations allows clinicians to optimize therapy and improve outcomes (86) . Identifying genetic variants that are related to drug metabolism or transport can be useful in determining risks of toxicities or efficacy for individual patients receiving chemotherapy. The FDA has recommended consideration of pharmacogenomics in package insert labeling for commonly used cancer therapies, which are currently being updated (87) .
A few examples of significant genetic polymorphisms that have been studied and incorporated in package inserts include TPMT, UDP-glucuronosyltransferase 1A1 (UGT1A1), and dihydropyrimidine dehydrogenase (DPD) (85) .
Polymorphisms of TPMT enzyme activity are variable among individuals and have demonstrated a correlation between 6-MP efficacy and adverse effects. TPMT is an enzyme that inactivates 6-MP; therefore, deficiency in this enzyme causes increased concentrations of active drug, leading to severe toxicity (e.g. myelosuppression) requiring dose reduction. Consequently, the FDA recommends that patients be genotyped for TPMT deficiency before starting 6-MP therapy (85) .
Other pertinent chemotherapy agents with genetic implications are irinotecan and 5-FU/capecitabine. The UGT1A1 enzyme plays an important role in glucuronidation and metabolism of irinotecan. Polymorphism of UGT1A1 results in decreased glucuronidation, resulting in increased drug concentrations and toxicity. Individuals who are homozygous for the UGT1A1*28 allele have demonstrated increased risk for neutropenia with irinotecan, thus a reduced dose is recommended. Patients heterozygous for the UGT1A1*28 allele may also be at increased risk for neutropenia.
Patients with low DPD activity are at higher risk of toxicities of 5-FU/capecitabine (e.g. myelosuppression, mucositis, hand-foot syndrome) because of increased drug exposure (85, 87) .
Pharmacogenetic testing may add to the overall cost of drug treatment and development; however, it can AIN, acute interstitial nephritis; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; EGFR, epidermal growth factor receptor; GI, gastrointestinal; HER-2, human epidermal growth-factor receptor 2 protein; NSCLC, non-small cell lung cancer; sCr, serum creatinine; ULN, upper limit of normal; VTE, venous thromboembolism.
potentially improve outcomes and reduce overall health care costs by mitigating management of adverse effects (87) .
Conclusion
Transplant recipients are at increased risk of malignancies after transplantation as a result of several risk factors, including immunosuppression and oncogenic viruses. In addition, given immunosuppression-reduction strategies and/or specific cancer treatments, patients may also be at an increased risk of rejection with cancer. Therapy options range from decades-old therapies to newer targeted therapies. The use of chemotherapy requires additional considerations for transplant recipients; side effects, organ dysfunction, and drug interactions should all be considered.
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